Back to Ovarian Cancer
NCT01040312
NCT01040312
Who may be able to join
Who might be able to join this trial:
- You have been diagnosed with one or more of the following cancers: small cell lung cancer, non-small cell lung cancer, cervical cancer, ovarian cancer, or stomach (gastric) cancer
- You have a specific genetic variation (a gene type called UGT1A1) that falls into one of these patterns: *1/*6, *1/*28, *6/*6, *28/*28, or *6/*28 (confirm with trial site)
- You are currently being treated with a chemotherapy drug called CPT-11 (irinotecan) combined with a platinum-based drug (such as cisplatin, carboplatin, or nedaplatin), with or without other targeted therapy drugs
Who may not be able to join:
- You have a medical reason why you cannot safely take the chemotherapy drug CPT-11 (irinotecan) (confirm with trial site)
- Your general health and ability to carry out daily activities is severely limited, rated as a 3 or 4 on a standard medical scale where 0 means fully active and 4 means completely unable to care for yourself
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Trial details
Status
Completed
Phase
Not Applicable
Sponsor
Daiichi Sankyo Co., Ltd.
Registry
clinicaltrials_gov
Start date
15 October 2009
Est. completion
29 September 2014
Where this trial is recruiting
🇯🇵 Japan
Primary endpoints
Number of Participants with UGT1A1 Genotype with Severe Toxicities Induced by CPT-11 with Platinum Analogues
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.